Achillion Picks Science Chief Deshpande to Succeed CEO Kishbauch
This article is for subscribers only.
Achillion Pharmaceuticals Inc., the maker of experimental hepatitis C therapies, said the company’s top scientist Milind Deshpande had been chosen to succeed retiring Chief Executive Officer Michael Kishbauch.
Deshpande, also the president of research and development, will take over after a three-month transition, Achillion said today in a statement. He joined the New Haven, Connecticut-based company in 2001 and has been its top scientist since June 2007. Kishbauch, CEO since July 2004, will remain a member of the company’s board.